Szpital Specjalistyczny Im. Henryka Klimontowicza W Gorlicach
- Address
- Ul. Wegierska Nr 21, 38-300 Gorlice, Poland
Szpital Specjalistyczny Im. Henryka Klimontowicza W Gorlicach - Advanced Lung Cancer Research Center
Szpital Specjalistyczny Im. Henryka Klimontowicza W Gorlicach is a specialized medical facility conducting cutting-edge clinical research in advanced non-small cell lung cancer (NSCLC). The center demonstrates particular expertise in investigating novel therapeutic approaches for patients with metastatic and locally advanced lung cancer, focusing on both squamous and non-squamous subtypes of this challenging disease.
- Treatment-naïve metastatic squamous NSCLC with pembrolizumab-based immunotherapy combinations
- Targeted therapy for KRAS G12C mutation-positive non-squamous NSCLC
- First-line treatment strategies combining immunotherapy with chemotherapy and novel targeted agents
The research center is actively engaged in phase III clinical trials evaluating innovative treatment combinations, including immune checkpoint inhibitors and targeted molecular therapies. Their clinical trial portfolio includes investigations of maintenance therapy strategies and precision medicine approaches for patients with specific genetic mutations, such as the KRAS G12C mutation. This focus on personalized treatment approaches positions the center at the forefront of advancing care for patients with previously untreated, locally advanced or metastatic lung cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Specjalistyczny Im. Henryka Klimontowicza W Gorlicach
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Study of MK-1084 and Pembrolizumab vs. Pembrolizumab and Placebo in First-Line KRAS G12C-Mutant Metastatic NSCLC with PD-L1 ≥50% | Merck Sharp & Dohme LLC | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | 2024-11-14 | 2025-06-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.